2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 572

Immunization With Hepatitis B Vaccine Accelerates SLE-Like Disease In An Animal Model
Abstract Number: 2739

Immunochip Analysis Identifies New Susceptibility Loci For Systemic Sclerosis: Implications For Pathogenesis
Abstract Number: 1444

Immunogenicity Induced By Tumor Necrosis Factor Antagonists In Chronic Inflammatory Arthropathies: Retrospective Study In Clinical Practice Conditions
Abstract Number: 2628

Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Abstract Number: 2484

Immunogenicity Of TNFα Blockers In Patients With Psoriatic Arthritis
Abstract Number: 1509

Immunogenicity, Adalimumab Levels and Clinical Response In Ankylosing Spondylitis Patients During 24 Weeks Of Follow-Up
Abstract Number: 2727

Immunologic and Inflammatory Markers Of Impending Disease Flare In Systemic Lupus Erythematosus Patients Not Taking Immunosuppressive Medications In The Biomarkers Of Lupus Disease (BOLD) Study
Abstract Number: 1864

Immunologic Markers and Molecular Mechanisms Associated With Increased Systemic Lupus Erythematosus Activity In Patients Not Taking Immunosuppressive Medications
Abstract Number: 1276

Immunologic Monitoring and Infectious Complications In Pediatric Rheumatology Patients Treated With Rituximab
Abstract Number: 963

Impact Of a Nurse-Led Program On Comorbidity Management In Rheumatoid Arthritis (RA): Results Of a Prospective, Multicenter, Randomized, Controlled Trial
Abstract Number: 2684

Impact Of Anti-Rheumatic Treatment On Immunogenicity Of Pandemic H1N1 Influenza Vaccine In Patients With Arthritis
Abstract Number: 1174

Impact Of Bariatric Surgery On Serum Urate Targets in People With Morbid Obesity and Diabetes: A Prospective Longitudinal Study
Abstract Number: 1808

Impact Of Baseline Disease Severity and Treatments On Outcomes In Clinical Trials Of SLE: Results From The Soccit Program
Abstract Number: 1026

Impact Of Basing Rheumatoid Arthritis Disease Activity Measurement and Treatment Recommendations On Patient Instead Of Physician Joint Assessments
Abstract Number: 1038

Impact Of Biological Treatment On Overall Mortality and On Incidence Of Second Cancers In Arthritis Patients – A Follow-Up Study From The Danish Danbio Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].